Catalys Pacific is an investment fund managing more than $132 billion ran by Brian Slingsby. There are currently 3 companies in Mr. Slingsby’s portfolio. The largest investments include Mineralys Therapeutics, Inc. and Hillevax, Inc., together worth $125 billion.
As of 6th August 2024, Catalys Pacific’s top holding is 9,194,579 shares of Mineralys Therapeutics, Inc. currently worth over $108 billion and making up 81.2% of the portfolio value.
In addition, the fund holds 1,208,974 shares of Hillevax, Inc. worth $17.5 billion.
The third-largest holding is Phathom Pharmaceuticals Inc worth $7.44 billion.
Currently, Catalys Pacific's portfolio is worth at least $132 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Catalys Pacific office and employees reside in Tokyo, Japan. According to the last 13-F report filed with the SEC, Brian Slingsby serves as the Managing Director at Catalys Pacific.
Brian Slingsby disclosed a decreased stake in Hillevax, Inc. by approximately 0.1%.
This leaves the value of the investment at $17.5 billion and 1,208,974 shares.
The two most similar investment funds to Catalys Pacific are Counterweight Ventures and Mork Capital Management. They manage $132 billion and $133 billion respectively.
Catalys Pacific’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 5.6% of
the total portfolio value.
The fund focuses on investments in the United States as
33.3% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
approximately 0.1% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $338 million.
These positions were updated on August 13th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Mineralys Therapeutics, Inc. |
No change
9,194,579
|
$107,576,574,000 | 81.19% |
| Hillevax, Inc. |
7.64%
1,208,974
|
$17,481,764,000 | 13.19% |
| Phathom Pharmaceuticals Inc |
No change
721,962
|
$7,436,208,000 | 5.61% |
| No transactions found | |||
| Showing first 500 out of 3 holdings | |||